absence of immunosuppressive treatment, (2) the prevenments in transplantation medicine improved the short-and tion of nonimmunologic causes of graft loss, such as ischelong-term survival of solid-organ transplantation. However, mia-reperfusion injury and arteriosclerosis, and (3) xenochronic allograft rejection, the side effects of the long-term transplantation as a potential solution for organ shortage.
immunosuppressive treatment, and organ shortage are still the Gene therapy has the potential to meet these chalmajor obstacles to achieving long-term survival. Gene therapy has the potential to meet these challenges and has unique lenges and has unique advantages in transplantation.
advantages in transplantation. In this review we summarize Allotransplantation requires the removal of tissues from the studies using gene therapy in solid-organ transplantation.
one individual and offers the possibility of treating cells or organs ex vivo with gene transfer vectors prior to implantation, thus avoiding many of the hurdles encounThe introduction of new immunosuppressive medicatered with in vivo gene transfer. This gives the advantage tions significantly increased the short-term and long-term of local production of immunosuppressive molecules, survival of kidney grafts from both living and cadaver without exposing the recipient to the systemic sidedonors. The projected half-life of cadaver transplantaeffects of the drugs and may potentially achieve antigen tion was increased to 13.8 years, and living-related transspecific immunosuppression. Higher concentrations of plantation was increased to 21.6 years in 1995. Despite vector can be administered to organs ex vivo or cells in the reduction of the rate of acute rejection, it is still one vitro, and excess vector washed away, decreasing chances of the major obstacles to achieving long-term survival.
for toxicity, immunogenecity, and systemic transduction The projected half-life of cadaver transplants with an or expression of the vector. One of the major limitations episode of acute rejection was only increased to 8.8 years to the gene therapy is that gene expression and protein from 7.0 years [1] . Chronic rejection remains the most production are transient, which significantly limits the important cause of graft loss in long-term studies, and ability of gene transfer techniques for the treatment of acute rejection is the major predictor of chronic rejecinborn errors of metabolism, genetic deficiencies, or tion. Death with graft function is increasingly becoming chronic disease. However, in the setting of transplantaan important cause of graft loss, occurring in 10 to 40% tion, transient gene expression may be sufficient for imof transplanted patients, due to long-term immunosupmune modulation or even desirable because the potenpressive treatment in particular the increased risk of intial toxicities and adverse effects of prolonged vector fection, malignancy, and cardiovascular disease [2] . Depersistence and expression or immunosuppressive molelayed graft function is another independent risk factor cule production could be avoided [4] . for long-term survival [3] . Another hurdle in transplantaGene therapy can be used for the transfer of gene that tion is the increasing number of patients on a waiting induces secreted proteins [such as interleukin-10 (IL-10), list because of organ shortage, limiting the opportunities transforming growth factor-␤ (TGF-␤)], overexpression for transplantation. To overcome these obstacles, three of membrane-bound molecules (such as Fas ligand) or main research areas in the field of transplantation have inintracellular proteins (such as antiapoptotic molecules). creased interest: (1) the prevention of acute and chronic
In this review, we summarize the studies using gene rejection with new immunotherapies with less systemic therapy in solid-organ transplantation. immunosuppression and preferably that induce transplantation tolerance, as defined by graft acceptance in the S-57 cells, B cells, macrophages, cytokines, and chemokines. studied in the context of the Th1/Th2 paradigm. This paradigm proposes that Th1-derived cytokines (IL-2, T cell recognizes the antigenic peptides in the groove of major histocompatibility complex (MHC) molecules on interferon ␥) promote allograft rejection by mediating delayed-type hypersensitivity reactions, cytotoxic T-lymthe surface of antigen-presenting cells (APCs). This socalled signal 1 delivers intracellular signals and confers phocyte generation, and macrophage activation and that Th2-derived cytokines (IL-4 and IL-10) protect rejection antigen specificity to the immune response but alone is insufficient for full T-cell activation. The second signal, by down-regulating immune responses. Previous studies in rat transplantation models showed that the induction or "costimulatory signal," is provided by interactions between specific receptors on the T cells, CD28, CTLA4 of tolerance in some studies is associated with the inhibition of Th1 cytokines and the sparing Th2 cytokines [15] . (CD152), CD40 ligand, and their respective ligands on APCs, B7-1 (CD80), B7-2 (CD86), and CD40. Block-TGF-␤ can also suppress T-cell, B-cell, neutrophil, and inflammatory cytokine functions. Many studies have ining the costimulatory signals with the fusion protein CTLA4Ig and/or anti-CD40 ligand antibodies results in vestigated the role of these immunomodulatory cytokines by using gene therapy. IL-10 gene therapy by using long-term allograft acceptance [5] .
Although allo-MHC is the main target for alloimmune different vectors (such as, naked plasmid DNA, retroviral, herpes simplex viral and adenoviral vector or lipid response, exposure of these donor MHC antigens through the thymus or hematopoietic stem cells could serve as a mediated) significantly prolonged murine and rabbit cardiac allograft survival [16] [17] [18] [19] . In addition, TGF-␤ gene strategy for inducing antigen-specific tolerance [6] . The involution of the adult thymus makes the thymic aptherapy was shown to prolong the murine cardiac and liver allograft survival [16, 20, 21] . Along with the immuproach not feasible for human gene therapy. However, DNA-mediated gene transfer of MHC classes I and II nosuppressive properties of TGF-␤, it induces fibrosis and may play a role in chronic rejection. This issue has molecules to recipient bone marrow cells prolonged survival of murine cardiac allografts [7] . By using a similar not been addressed in these studies. One recent study investigated the effects of IL-4 gene therapy by using approach, it was shown that pretransplant administration of a single donor class I MHC molecule was sufficient for recombinant adenovirus vector in rat heart transplantation model. Although IL-10 gene therapy significantly the indefinite survival of cardiac allografts [8] . Retroviral transduction of bone marrow with the donor MHC gene prolonged the cardiac allograft survival, IL-4 gene therapy had no effect [22] . significantly prolonged murine skin allograft survival and miniature swine kidney allograft survival [9, 10] . A recent Chemokines are members of a family of small, inducible, and secreted proteins that are produced in instudy, using liposomes to transfect cultured recipient hepatocytes with plasmid DNA encoding the soluble flammation and regulate leukocyte and lymphocyte recruitment. Increasing number studies have shown that donor MHC class I Ag, abrogated HAR and prolonged allograft survival in presensitized rat cardiac allograft chemokines play an important role in allograft rejection [23] . vMIP-II and MC148 are two recently identified model [11] . These studies demonstrate that the application of gene therapy of donor MHC molecules through chemokine homologues encoded by human herpes virus 8 and molluscum contagiosum that have antagonistic bone marrow cells provides a new strategy for inducing transplantation tolerance.
activities against multiple different CC and CXC chemokine receptors. Plasmid-mediated gene transfer of either Systemic administration of CTLA4Ig and anti-CD40 ligand has been tested in numerous allograft and xenochemokine antagonists markedly prolonged vascularized and nonvascularized cardiac allograft survival in mice graft models, and it has been shown in some studies that they significantly prolong survival and induce antigen- [24] . This approach resulted in a marked decrease of donor-specific cytotoxic T lymphocytes infiltrating the specific tolerance [5] . The effect of local expression of CTLA4Ig has been studied by using replication-defecgrafts and inhibited alloantibody production. Targeting the chemokine functions by gene therapy can be another tive adenoviral vector in cold-preserved murine liver allograft model. This method induced indefinite survival novel approach for inhibition of alloimmune response. Following the activation of effector mechanisms, alloof the recipient with donor-specific unresponsiveness [12] . Ex vivo perfusion of the donor hearts with recombiimmune responses need to be down-regulated. This is carried out by several mechanisms that inhibit T cells at nant adenovirus encoding CTLA4Ig cDNA induced indefinite graft survival in rat cardiac allotransplantation the later stages of the alloimmune response. CTLA4 molecules expressed on activated T cells interact with [13] . Transplantation of allogenic mouse islets expressing the human CTLA4Ig cDNA following gene gun delivery B7 molecules on APCs and deliver inhibitory signals to T cells. The Fas/Fas ligand (FasL) system plays an also prolonged allograft survival significantly [14] . Gene transfer of anti-CD40 ligand has not yet been studied.
important role in the induction of lymphoid apoptosis and can turn off immune responses. Two immune-priviThe role of cytokines in the induction of allograft acceptance and transplantation tolerance has been largely leged sites, the eye and the testis, constitutively express
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FasL and protect cells from immune destruction. Gene prevent antibody-induced transplant arteriosclerosis in mouse cardiac allografts [32] . therapy, using FasL, has been studied by several groups Endothelium-derived nitric oxide is an endogenous in different transplantation models, but the results are inhibitor of vascular lesion formation. Gene transfer of controversial. Gene transfer of murine FasL by replicaendothelial cell nitric oxide synthase by the Sendai virus/ tion defective adenovirus significantly prolonged rat reliposome in vivo gene transfer technique to the endothenal allograft survival [25] . Similar results were obtained lium of rat carotid arteries significantly decreased the in the rat liver transplantation model by using rat pFasL balloon injury-induced damage and neointima formation conjugated to liposome vesicles (hemagglutinating virus [33] . Adenoviral-mediated inducible nitric oxide synof Japan liposome) [26] . However, heart allografts from thase gene transfer completely suppressed the developFasL transgenic mice were more rapidly rejected than ment of arteriosclerosis in both untreated or cyclosporine nontransgenic control allografts [27] .
A-treated rat aortic allografts [34] . A recent interesting study demonstrated the imporIntercellular adhesion molecule-1 (ICAM-1) is an tance of secondary lymphoid tissue in alloimmune reimportant mediator of cell adhesion and T-cell costimusponse. In this study, cardiac allografts were accepted inlation. The use of ex vivo hyperbaric transfection of antidefinitely in recipient mice that lack secondary lymphoid sense oligodeoxynucleotides that blocked ICAM-1 retissue, indicating that the alloimmune response to a vassulted in the reduction of chronic graft vascular disease cularized organ cannot be initiated in the graft itself and and reperfusion injury in rat cardiac allografts [35, 36] . requires the presence of secondary lymphoid tissue [28] .
Cyclin-dependent kinase 2 is an important enzyme in This study may challenge the idea of using gene therapy the transition from the G1-S phase of the cell cycle and methods locally at the transplanted organ and may sugmediates smooth muscle cell proliferation. The use of gene gest that secondary lymphoid organs could be potential transfer of antisense phosphorothioate oligodeoxynucletargets. Dendritic cells are highly specialized APCs that otide against this enzyme inhibited intimal hyperplasia initiate and modulate immune responses and play an and expression of vascular cell adhesion molecule-1 [37] . essential role in T-cell activation and central and peripheral tolerance. A recent study used dendritic cells for XENOTRANSPLANTATION adenoviral delivery of CTLA4Ig and induced alloantigen-specific T-cell hyporesponsiveness [29] .
Organ shortage is one of the major limitations in transplantation, and this has stimulated a great deal of research into the possibility of using nonhuman donors for MODULATION OF NONIMMUNOLOGIC transplantation. The preferred donor animal species for CAUSES OF GRAFT LOSS xenotransplantation is the pig. The initial barrier to xenoIschemia-reperfusion injury is an important cause of transplantation is hyperacute rejection (HAR), which early nonimmune loss of the allograft. It induces the results in the loss of graft within a few minutes to hours formation of reactive oxygen species by endothelial dambecause of antibody-mediated complement activation of age, which may cause cell death within the graft or may the graft endothelium. This xenoreactive natural antiinduce acute or chronic rejection by activating cytokines body predominantly recognizes the unique carbohydrate and adhesion molecules and recruiting leukocytes. This structure, Gal␣1-3Gal, which is found as the terminal subject has also been of interest in gene therapy. Mitosugar on glycolipids and glycoproteins present on the chondrial superoxide dismutase gene was transferred to donor pig endothelium. Humans do not express this antithe mouse liver prior to the lobar ischemia-reperfusion gen and have antibody to this antigen, in a similar fashion injury. It was shown to reduce acute liver damage signifito blood group antigens. This epitope is synthesized by cantly by inhibiting the redox-mediated activation of nuan enzyme called ␣-galactosyltransferase. It was shown clear factor-B and activator protein-1, which are the that introducing a functioning gene that encodes this immediate early transcription factors that represent comenzyme by retroviral gene transfer into autologous bone mon pathways by which cells respond to environmental marrow cells overcame the HAR in a mouse model [38] . stress [30] .
The effector mechanism of HAR is the activation of comApoptosis plays an important role in organ preservaplement cascade. There are complement-regulatory protion and rejection. Overexpression of antiapoptotic genes teins (CRPs) present on the donor endothelium that in the allograft may prevent ischemia/reperfusion-induced regulate the activation of complement. These proteins apoptosis. Bcl-2 gene transfer to the mouse liver by reinclude decay-accelerating factor (DAF;CD55), memcombinant adenovirus before procurement significantly brane cofactor protein (MCP;CD46), and CD59. Xenodecreased hepatocyte injury and the number of apoptotic graft endothelium is severely damaged because of a lack cells [31] . It was also demonstrated that the expression of these CRPs. Transgenic pigs that express human CRPs have been developed to limit complement-induced damof genes that encode heme oxygenase-1, bcl-xl, and A20 S-59 
